ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: knee

Antiphospholipid Syndrome: The Risk of Travel at High Altitudes

Antiphospholipid Syndrome: The Risk of Travel at High Altitudes

Vaneet Kaur Sandhu, MD, & Kathleen Teves, MD  |  August 16, 2018

Antiphospholipid syndrome (APS) is an autoimmune clotting disorder that may present catastrophically with multiple thromboses over a short period of time. In this article, we examine the case of a woman with undiagnosed APS whose first symptoms presented during a long-haul flight. A review of the literature on thrombosis at high altitudes and during long…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Antiphospholipid Antibody Syndrome (APS)blood clotHughes Syndrome

Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  August 15, 2018

New research shows tanezumab may be safe and effective for patients with osteoarthritis pain…

Filed under:Drug Updates Tagged with:filgotinibhipkneeKnee Osteoarthritis (OA)osteoarthritis (OA)Painpsoriatic arthritistanezumab

Lyme Arthritis Treatment Protocols Critical as Lyme Disease Spreads

Carina Stanton  |  August 15, 2018

As Lyme disease and Lyme arthritis spread to new regions in North America, physicians may ned to become aware of their signs and symptoms. Allen C. Steere, MD, says “Lyme arthritis is more complicated to treat than other manifestations of the disease.” Here are some best practices for treating Lyme arthritis…

Filed under:Conditions Tagged with:best practicesBorrelia burgdorferiLyme arthritisLyme Disease

ACR Advocates for Access to Viscosupplementation for OA

Kelly Tyrrell  |  August 6, 2018

In several U.S. states, Blue Cross/Blue Shield and other insurers have dropped or are considering dropping coverage of hyaluronic acid injection—or viscosupplementation—for patients with knee osteoarthritis. The decision appears to be based on guidelines published by the American Academy of Orthopaedic Surgeons in 2013, which at that time specified that research had not found hyaluronic…

Filed under:Professional Topics Tagged with:American Academy of Orthopaedic SurgeonsCommittee on Rheumatologic Care (CORC)dropping coveragehyaluronic acid injectionknee osteoarthritisviscosupplementation

Don’t Rule Out Placebos for Osteoarthritis Pain Control

Thomas R. Collins  |  July 19, 2018

CHICAGO—The placebo effect in treating pain in osteoarthritis (OA) should not be discounted, an expert said at the ACR State-of-the-Art Clinical Sym­posium in April. It’s especially important to accept the effect as real considering that trials of pain therapies in OA generate such high placebo effects (typically at least 40%) and that OA treatment options,…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:2018 State of the Art Clinical Symposiumalternative therapiesplacebo

Patient Education Videos Help Them Understand & Manage Their Disease

Kathy Holliman, MEd  |  July 19, 2018

Videos designed to help patients understand and manage chronic rheumatologic diseases can lead to gains in clarity about the disease duration, symptoms, medications, and the importance of regular visits with a physician. A study published in a recent issue of Arthritis Care & Research looks at the development and impact of three educational videos for…

Filed under:Patient Perspective Tagged with:patient communicationpatient educationpatient management

The Demise of the Inpatient Rheumatology Unit

Ruth Jessen Hickman, MD  |  July 19, 2018

Through much of the 20th century, dedicated rheumatic disease units were found in hospitals across the U.S. and countries around the world. In the latter part of the century, this began to change, with hospitals moving toward the consult model of care for rheumatic patients. This change reflects larger shifts in the medical world toward…

Filed under:Practice Support Tagged with:inpatientoutpatient

Figures 1 and 2: These images shows the patient’s bilateral ulnar deviation and benediction deformity of the left hand.

Learn to Spot Neuropathic Arthropathy Mimicking RA

Carlos Antonio Moura, MD, Nathalia Crusoé, MD, Marília Cruz, MD, & Carlos Geraldo Moura, MD  |  July 19, 2018

Rheumatoid arthritis (RA) is characterized by polyarthritis, especially involving hands and wrists. Without treatment, RA usually evolves to articular deformities. Unfortunately, although rheumatoid deformities are characteristic, they are not pathognomonic, and we should be aware of possible mimics.1 Neuropathic arthropathy (NA), similar to other diseases, such as hemochromatosis, psoriatic arthritis, calcium pyrophosphate deposition disease, Jaccoud…

Filed under:Rheumatoid Arthritis Tagged with:mimics

A Comprehensive Review of NSAID Cardiovascular Toxicity

A Comprehensive Review of NSAID Cardiovascular Toxicity

Deepan S. Dalal, MD, MPH, Maureen Dubreuil, MD, MS, & David T. Felson, MD, MPH  |  July 18, 2018

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….

Filed under:Analgesics Tagged with:acetaminophencelecoxib (Elyxyb)diclofenacIbuprofennaproxenNSAIDsrofecoxib

Can Rheumatologists Get More Systematic about Psychosocial Care?

Larry Beresford  |  June 21, 2018

A recent position statement by the Society of Behavioral Medicine (SBM) concludes that patients with persistent pain need better access to psychosocial care in all healthcare settings.1 The SBM offers 10 health policy recommendations for improving such access, including removing system-related barriers, providing referral tools, reimbursing for evidence-based psychosocial approaches, prioritizing generalist-level and specialist pain…

Filed under:ConditionsPatient Perspective Tagged with:Association of Rheumatology Professionals (ARP)interdisciplinaryopioid crisisphysician patient relationshippsychosocial

  • « Previous Page
  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • 37
  • …
  • 79
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences